Treats cardiac decompensation due to depressed contractility. ANDA 74086, held by Hospira. Dobutamine Hydrochloride.
As of Nov 16, 2026, ANDA 74086 (Dobutamine Hydrochloride), held by Hospira, was first approved by FDA on Nov 29, 1993, with 6 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Dobutamine Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine hydrochloride.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 29, 1993 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dobutamine HydrochlorideEQ 12.5MG BASE/ML · injectable;injection | Dobutamine Hydrochloride | Rx |
| Dec 31, 2002 | Supplement 8Manufacturing | Approved | None posted |
| Oct 23, 1997 | Supplement 7Manufacturing | Approved | None posted |
| Apr 7, 1997 | Supplement 5Labeling | Approved | None posted |
| Dec 2, 1996 | Supplement 4Labeling | Approved | None posted |
| Oct 3, 1996 | Supplement 3Manufacturing | Approved | None posted |
| Jun 7, 1994 | Supplement 1Manufacturing | Approved | None posted |
| Nov 29, 1993 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters